1. Home
  2. IRWD vs BWAY Comparison

IRWD vs BWAY Comparison

Compare IRWD & BWAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IRWD
  • BWAY
  • Stock Information
  • Founded
  • IRWD 1998
  • BWAY 2003
  • Country
  • IRWD United States
  • BWAY Israel
  • Employees
  • IRWD N/A
  • BWAY N/A
  • Industry
  • IRWD Biotechnology: Pharmaceutical Preparations
  • BWAY Medical/Dental Instruments
  • Sector
  • IRWD Health Care
  • BWAY Health Care
  • Exchange
  • IRWD Nasdaq
  • BWAY Nasdaq
  • Market Cap
  • IRWD 251.8M
  • BWAY 280.7M
  • IPO Year
  • IRWD 2010
  • BWAY 2019
  • Fundamental
  • Price
  • IRWD $3.11
  • BWAY $14.96
  • Analyst Decision
  • IRWD Buy
  • BWAY Strong Buy
  • Analyst Count
  • IRWD 5
  • BWAY 2
  • Target Price
  • IRWD $5.34
  • BWAY $20.50
  • AVG Volume (30 Days)
  • IRWD 3.2M
  • BWAY 68.1K
  • Earning Date
  • IRWD 11-10-2025
  • BWAY 11-11-2025
  • Dividend Yield
  • IRWD N/A
  • BWAY N/A
  • EPS Growth
  • IRWD N/A
  • BWAY 189.46
  • EPS
  • IRWD 0.18
  • BWAY 0.13
  • Revenue
  • IRWD $338,987,000.00
  • BWAY $49,094,000.00
  • Revenue This Year
  • IRWD N/A
  • BWAY $335.63
  • Revenue Next Year
  • IRWD N/A
  • BWAY $22.10
  • P/E Ratio
  • IRWD $17.56
  • BWAY $47.49
  • Revenue Growth
  • IRWD N/A
  • BWAY 27.08
  • 52 Week Low
  • IRWD $0.53
  • BWAY $7.84
  • 52 Week High
  • IRWD $5.13
  • BWAY $17.92
  • Technical
  • Relative Strength Index (RSI)
  • IRWD 74.04
  • BWAY 40.45
  • Support Level
  • IRWD $1.88
  • BWAY $14.75
  • Resistance Level
  • IRWD $3.47
  • BWAY $16.63
  • Average True Range (ATR)
  • IRWD 0.33
  • BWAY 0.70
  • MACD
  • IRWD 0.12
  • BWAY -0.19
  • Stochastic Oscillator
  • IRWD 79.56
  • BWAY 6.41

About IRWD Ironwood Pharmaceuticals Inc.

Ironwood Pharmaceuticals Inc is a specialty and generic drug manufacturing company that operates a human therapeutics segment. The company is focused on advancing product opportunities in areas of large unmet need, including irritable bowel syndrome with constipation, chronic idiopathic constipation, hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease, and vascular and fibrotic diseases. The company considers collaborative licenses, commercial agreements, and acquisition investment to be potential components of its operational growth plan for expanding its research, development, manufacturing, and marketing capabilities.

About BWAY BrainsWay Ltd.

BrainsWay Ltd is engaged in advanced noninvasive neurostimulation treatments for mental health disorders. The company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. Current indications include depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. The company derives revenues from the lease and sale of Deep TMS systems.

Share on Social Networks: